news
-
8 September 2022Sequana Medical announces H1 2022 results and provides business update
Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces its business highlights and financial results for the six-month period ending 30 June 2022 and its outlook for the remainder of the year and beyond.
Ian Crosbie, Chief Executive Officer at Sequana Medical, commented: “We have made important progress with both our liver disease and heart failure programs during this reporting period. Our POSEIDON study for the alfapump in patients with liver disease continues to report strong interim results, including 70% 12 month survival for the Roll-In cohort, and we look forward to reporting primary endpoint data for the Pivotal cohort by year end. We are excited to see the continued strong clinical evidence of a disease-modifying profile for our DSR program for diuretic-resistant heart failure patients. In addition to no congestion-related re-hospitalizations during their study follow-up, which is remarkable given that typically one in four of these patients is re-admitted within a month of discharge, the 75% reduction in predicted 12 month mortality is highly promising for this patient group in need of improved clinical options. The evidence from our proof-of-concept studies show the long-term clinical benefits delivered by Short Term DSR therapy and we look forward to further demonstrating DSR’s potential in MOJAVE, our upcoming US phase 1b/2a multi-centred, randomized, controlled study with DSR 2.0, our second-generation DSR product.
“Finally, the two highly experienced US medtech executives that we have added to our Board bring important expertise as we prepare for US commercialization of the alfapump, and we are well capitalised into Q3 2023 having successfully raised additional finance.”
Related
Alexandra Clyde appointed to Sequana Medical Board of Directors
Sequana Medical secures EUR 10 million loan facility with Kreos Capital
Sequana Medical announces new Share Capital Amount and New Number of Shares
Sequana Medical receives certification under MDR, the new European Medical Device Regulation
Sequana Medical announces H1 2021 results and provides business update
Sequana Medical appoints Jackie Fielding, former Medtronic VP, to its Board of Directors
Sequana Medical announces first patient enrolled in SAHARA DESERT
Sequana Medical announces 2020 Full Year Results and 2021 Outlook
Sequana Medical announces granting of key alfapump DSR® patents in U.S. and Europe
Sequana Medical announces H1 2020 results and provides business update
Sequana Medical announces €7.3 million debt financing and provides clinical update
Sequana Medical announces 2019 Full Year Results and 2020 Outlook
Sequana Medical announces new share capital amount and new number of shares
Sequana Medical announces 2019 Half Year Results and Year-to-date Business Update
Sequana Medical appoints leading experts as Heart Failure Scientific Advisors
Sequana Medical to host webcast on 27 May 2019
Sequana Medical announces 2018 Full Year Results and 2019 Outlook
Sequana Medical raises €27.5 million in successful Initial Public Offering
Sequana Medical Announces Publication of Results of Multicentre Randomized Controlled Study
Sequana Medical Announces Results of the MOSAIC trial data presented at 2017 AASLD
Sequana Medical Announces Sudden Passing of Founder, President & CEO
Ian Crosbie Joins Sequana Medical as Chief Financial Officer
Sequana Medical has been selected as a finalist for the 2012 MEDTEC EMDT Innovation Awards
Sequana Medical receives CE Mark Approval for the ALFApumpTM System and adds key executive to team
NovaShunt announces the launch of its new corporate identity: Sequana Medical